Nicotinamide mononucleotide supplementation rescues mitochondrial and energy metabolism functions and ameliorates inflammatory states in the ovaries of aging mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal (mouse) interventional study
PubMed 39355508 · doi:10.1002/mco2.727
What was done
Investigated the effects of nicotinamide mononucleotide (NMN) supplementation on age-related ovarian decline in aging mice. The researchers evaluated ovarian NAD+ concentrations, follicle counts, oocyte quality and quantity, serum hormone levels, antioxidant markers, and proinflammatory factors. Mechanisms were explored using scanning electron microscopy of granulosa cell mitochondria and lipid droplets, alongside transcriptomic profiling and validation assays.
What was found
The abstract reports directional findings without numerical values or effect sizes. NMN administration restored age-associated reductions in ovarian NAD+ levels, prevented ovarian atrophy, and increased follicle count as well as the number and quality of ovulated oocytes. It improved serum hormone secretion and antioxidant factors while downregulating proinflammatory markers. Morphological alterations in granulosa cell lipid droplets and mitochondria, paired with transcriptomic data, indicated improvements in energy metabolism, mitochondrial function, and inflammation.
Why it matters
Provides mechanistic evidence in a rodent model that restoring NAD+ with NMN can alleviate ovarian aging and preserve ovarian reserve, suggesting potential therapeutic targets for age-related fertility decline.
Limits
The study was conducted entirely in mice, and results may not translate directly to human female reproductive physiology. The abstract provides no sample sizes, dosing details, duration of exposure, or quantitative data (such as effect sizes, percentages, or p-values).